Gujarat Inject (Kerala) Ltd. (GUJINJEC) — Tipsheet

Gujarat Inject loses Chairman, CFO & Whole-Time Director in single death

Tipsheet Editorial — Wed, 24 Jun 2026 17:25:09 GMT

Deepak Diwan Bachwani died just weeks after taking charge following the MD's exit. The nano-cap's solar pivot now faces immediate execution risk.

What’s new

Deepak Diwan Bachwani, Chairman, CFO and Whole-Time Director, died on 23 June 2026.
He was appointed only weeks earlier after the MD resigned, centralising top strategy and finance.
Nano-cap had just pivoted to solar with ₹14.49 cr and ₹1.07 cr orders and a 7x revenue surge.

Why it matters

The loss of an executive who simultaneously held three critical leadership roles creates an immediate governance vacuum for a company with a ₹171 cr market cap. Bachwani was the architect of the solar pivot that drove a 7x revenue jump in Q4. Finding replacements quickly is now the pressing risk; delays could derail the order book.

What we’re watching

Whether the board can appoint a new Chairman and CFO within weeks.
Impact on the two recently won solar orders (₹14.49 cr and ₹1.07 cr).
Any further resignations or governance disclosures from the micro-cap.

The full read

Gujarat Inject (Kerala) has lost its Chairman, Whole-Time Director and Chief Financial Officer — all three roles held by the same person. Deepak Diwan Bachwani died on 23 June 2026, just weeks after he was appointed to replace the resigning managing director. He was the driving force behind the solar pivot that delivered a 7x revenue jump in Q4 and two recent orders worth ₹14.49 crore and ₹1.07 crore. For a nano-cap with a ₹171 crore market cap, the loss of an executive who simultaneously ran strategy and finance is a severe blow. The board now faces an immediate test: fill these roles fast or risk stalling momentum. The stock is likely to reflect this uncertainty.

Primary source: BSE · NSE

Gujarat Inject lands ₹14.49 cr solar order, nearly 40% of annual revenue

Tipsheet Editorial — Thu, 11 Jun 2026 17:08:55 GMT

Deon Energy's 16,129-module contract is the nano-cap's largest single order, a test of whether its solar pivot can scale.

What’s new

Gujarat Inject secured a ₹14.49 cr purchase order from Deon Energy for 16,129 solar PV modules.
The order is worth ~40% of the company's ₹36.3 cr FY26 revenue, its largest single contract to date.
Delivery is slated for June 2026, and it follows a string of smaller solar orders this quarter.

Why it matters

This is not a routine win for Gujarat Inject. At ₹14.49 cr, the order is roughly the same size as the ₹36.3 cr revenue the company booked in all of FY26. Coming from a new customer, it signals that the solar pivot is starting to produce material revenue and not just a pipeline of small orders. The open question is whether this is a one-off or the start of a new run-rate.

What we’re watching

The margin profile of this order, as solar modules are a commodity where procurement costs will matter.
Whether Deon Energy becomes a repeat customer or if Gujarat Inject can land similar-scale orders from others.
How the company funds the working capital to deliver ₹14.49 cr worth of panels by June 2026.

The full read

Gujarat Inject is a nano-cap that just landed an order the size of 40% of its annual business. Deon Energy has contracted 16,129 solar modules at ₹14.49 cr, the biggest single order since the company started pivoting to renewables. It follows a series of smaller wins from Earthwave Technology, Perfect Renewtech, Surja Infra, and Ottire Lifestyle over the past quarter. The scale is what matters. For a company that did ₹36.3 cr in revenue last year, with ₹31 cr of that in the final quarter alone, a ₹14.49 cr order from a new customer is not a rounding error. It is a new revenue tier. The pivot is no longer theoretical. It now has to prove it can execute at scale, and with a trailing ROE of just 1.0%, the balance sheet is not built for a ₹14.49 cr working-capital swing without financing.

Primary source: BSE · NSE

Gujarat Inject wins ₹1.07 cr solar module order from Ottire Lifestyle

Tipsheet Editorial — Mon, 08 Jun 2026 14:11:27 GMT

The nano-cap's fourth recent solar contract. The order equals 2.95% of its annual revenue.

What’s new

Gujarat Inject received a purchase order from Ottire Lifestyle for 1,334 solar PV modules rated at 600WP each.
The order is worth ₹1.07 crores, or about 2.95% of the company's annual revenue of ₹36.3 crores.
Delivery and site arrangement is due by the end of June 2026.

Why it matters

For a company with ₹36.3 crore in revenue, a single ₹1 crore order is modest. But Gujarat Inject has now disclosed four separate solar module contracts. The repeat wins from new counterparties signal a tangible business shift, not just talk. The open question is whether the margins on these sales justify the pivot.

What we’re watching

Whether the order book continues to grow or flattens at this run-rate.
The margin profile on solar module sales versus the company's legacy business.
Execution on the June 2026 delivery timeline for this contract.

The full read

Gujarat Inject (Kerala) Ltd, a nano-cap with a ₹167 crore market value, has won its fourth solar module contract. The ₹1.07 crore order from Ottire Lifestyle for 1,334 600WP modules is not a needle-mover for a company with ₹36.3 crore in annual revenue. But the repeat wins are the story. The order is worth 2.95% of annual revenue, crossing the materiality threshold for companies this size. Delivery is due by June 2026. The individual orders are small. The collective signal is not. Gujarat Inject is building a solar book, and the counterparty list is diversifying. The real test is whether the margins on these module sales justify the pivot.

Primary source: BSE · NSE

Gujarat Inject (Kerala) posts 7x revenue jump in Q4, flips to profit

Tipsheet Editorial — Wed, 20 May 2026 19:06:21 GMT

Q4 revenue surged to ₹30.7 cr from ₹4.2 cr a year earlier; net profit of ₹1.64 cr reverses losses. Capital work-in-progress of ₹20.8 cr signals a major expansion phase.

What’s new

Q4 revenue surged to ₹30.7 cr from ₹1.6 cr in preceding quarter and ₹4.2 cr a year ago.
Net profit of ₹1.64 cr in Q4, reversing recent losses.
Balance sheet shows ₹20.8 cr in capital work-in-progress, hinting at major expansion.

Why it matters

For a nano-cap, this is a material inflection point. The scale of the turnaround suggests either a large new contract or a fundamental business shift. The CWIP of ₹20.8 cr relative to full-year revenue of ₹36.3 cr means the company is investing heavily for future capacity—capital expenditure is outpacing current operations.

What we’re watching

Whether the revenue spike is sustainable or a one-off.
Progress on the capital work-in-progress converting to revenue-generating assets.
FY27 guidance or any management commentary; cash flow and debt levels given the expansion.

The full read

Gujarat Inject (Kerala) moved from near-zero revenue to ₹30.7 cr in a single quarter, propelling full-year revenue to ₹36.3 cr—almost double the prior year. Profitability returned with a net profit of ₹1.64 cr in Q4, reversing recent losses. More tellingly, the balance sheet now carries ₹20.8 cr in capital work-in-progress, a figure that represents more than half of the year's total revenue. This suggests the company is not just enjoying a one-off bump but actively expanding capacity—a rare move for a nano-cap. The open question is sustainability: can the company maintain this run rate, and how will it fund the expansion? The next quarterly numbers will be the real test.

Primary source: BSE · NSE

Gujarat Inject (Kerala) Q4 revenue zooms 19x to ₹30.7 cr

Tipsheet Editorial — Wed, 20 May 2026 19:01:28 GMT

Full-year FY26 revenue nearly doubles to ₹36.3 crore; net profit turns positive. Capital work-in-progress of ₹20.8 crore signals ongoing expansion.

What’s new

Q4 revenue surged to ₹30.7 cr from ₹1.6 cr in Q3 and ₹4.2 cr a year ago.
Full-year FY26 revenue nearly doubled to ₹36.3 cr.
Net profit for Q4 at ₹1.64 cr vs ₹0.038 cr in Q3; CWIP at ₹20.8 cr.

Why it matters

The Q4 numbers represent a dramatic turnaround for a nano-cap that was essentially dormant. The ₹20.8 cr in capital work-in-progress suggests management is betting on continuation, but the quality and durability of the revenue spike remain open questions.

What we’re watching

Whether Q4 revenue momentum sustains in FY27.
Details on the source of the revenue jump.
Any management commentary on the expansion plans.

The full read

Gujarat Inject (Kerala) reported a stunning Q4 FY26, with revenue jumping to ₹30.7 crore from just ₹1.6 crore in the previous quarter and ₹4.2 crore a year ago. Full-year FY26 revenue nearly doubled to ₹36.3 crore, meaning Q4 alone accounted for 85% of the full year. Net profit turned positive at ₹1.64 crore versus near-zero in Q3. The balance sheet also shows ₹20.8 crore in capital work-in-progress, pointing to ongoing capacity expansion. For a nano-cap that was barely generating revenue quarters ago, this is a material inflection—if it can be sustained. The open question is whether this reflects a one-off contract or the start of a new growth trajectory.

Primary source: BSE · NSE